Mary Rinella to Fatty Liver
This is a "connection" page, showing publications Mary Rinella has written about Fatty Liver.
Connection Strength
10.947
-
Review Article: Fibrosis Reversal in Metabolic Dysfunction-Associated Steatohepatitis-The Promise of Emerging Therapeutics. Aliment Pharmacol Ther. 2026 Nov; 64(9):1184-1196.
Score: 0.874
-
Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management. Nat Rev Gastroenterol Hepatol. 2026 Jun; 23(6):460-474.
Score: 0.849
-
Variance Between Clinical Guidance and Real-World Management of Metabolic Dysfunction-associated Steatotic Liver Disease in the United States. Clin Gastroenterol Hepatol. 2025 Feb; 23(2):374-376.e3.
Score: 0.763
-
Steatotic liver disease: a new name to reflect the combined role of alcohol and metabolic dysfunction. Nat Med. 2024 04; 30(4):933-936.
Score: 0.742
-
Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition": EASL, AASLD and ALEH stand united to advance the field of steatotic liver disease. J Hepatol. 2024 07; 81(1):e20-e21.
Score: 0.727
-
Defining an approach for therapeutic strategies in metabolic dysfunction-associated steatotic liver disease after liver transplantation. Hepatology. 2025 09 01; 82(3):766-776.
Score: 0.726
-
Authors' response. J Acad Nutr Diet. 2013 Feb; 113(2):211-2.
Score: 0.342
-
Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology. 2012 Nov; 56(5):1741-50.
Score: 0.336
-
A myriad of pathways to NASH. Clin Liver Dis. 2012 Aug; 16(3):525-48.
Score: 0.328
-
The role of diet and nutrient composition in nonalcoholic Fatty liver disease. J Acad Nutr Diet. 2012 Mar; 112(3):401-9.
Score: 0.321
-
Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease? Hepatology. 2011 Oct; 54(4):1118-20.
Score: 0.312
-
Dysregulation of the unfolded protein response in db/db mice with diet-induced steatohepatitis. Hepatology. 2011 Nov; 54(5):1600-9.
Score: 0.308
-
Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol. 2011 Jul-Sep; 10(3):277-86.
Score: 0.306
-
Non-alcoholic fatty liver disease: is bariatric surgery the answer? Clin Liver Dis. 2009 Nov; 13(4):689-710.
Score: 0.273
-
Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res. 2008 May; 49(5):1068-76.
Score: 0.242
-
Clinical Outcomes and Non-Invasive Testing in Metabolic Dysfunction-Associated Steatohepatitis With Cirrhosis: A Systematic Review. Liver Int. 2026 05; 46(5):e70608.
Score: 0.214
-
Comparative efficacy of phase 2-3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis: An updated network meta-analysis. Med. 2026 May 08; 7(5):101077.
Score: 0.213
-
The Relentless Progression of Metabolic Dysfunction-associated Steatotic Liver Disease in Liver Transplantation in Spain. Transplantation. 2026 Feb 01; 110(2):e444-e452.
Score: 0.207
-
Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial. Aliment Pharmacol Ther. 2025 Dec; 62(11-12):1089-1099.
Score: 0.207
-
Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2025 11; 10(11):998-1012.
Score: 0.205
-
Phosphatidylethanol in steatotic liver disease. J Hepatol. 2025 Nov; 83(5):1189-1203.
Score: 0.203
-
Call to action-Pediatric MASLD requires immediate attention to curb health crisis. Hepatology. 2025 11 01; 82(5):1341-1351.
Score: 0.202
-
Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis. J Gastroenterol. 2025 07; 60(7):891-904.
Score: 0.198
-
Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers. 2025 Mar 06; 11(1):14.
Score: 0.198
-
Risk Stratification for Chronic Kidney Disease After Liver Transplant for Metabolic Dysfunction-associated Steatohepatitis (MASH) Cirrhosis: Results From the NailMASH Consortium. Transplantation. 2025 03 01; 109(3):484-495.
Score: 0.193
-
Validating the new nomenclature of steatotic liver disease in patients with excessive alcohol intake - Authors' reply. Lancet Gastroenterol Hepatol. 2024 05; 9(5):409-410.
Score: 0.186
-
Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol Hepatol. 2024 03; 9(3):218-228.
Score: 0.183
-
The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol. 2004 Jan; 40(1):47-51.
Score: 0.182
-
Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition'. Ann Hepatol. 2024 Jul-Aug; 29(4):101178.
Score: 0.182
-
Steatotic liver disease, a useful construct in primary care that doesn't upset the apple cart. Hepatology. 2024 06 01; 79(6):1252-1254.
Score: 0.182
-
Dual-echo, chemical shift gradient-echo magnetic resonance imaging to quantify hepatic steatosis: Implications for living liver donation. Liver Transpl. 2003 Aug; 9(8):851-6.
Score: 0.177
-
Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transpl. 2001 May; 7(5):409-14.
Score: 0.151
-
Editorial: Age and Non-Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock? Am J Gastroenterol. 2017 05; 112(5):752-754.
Score: 0.115
-
Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015 Jun 09; 313(22):2263-73.
Score: 0.101